Review Article
Treatment of Frontal Fibrosing Alopecia
Table 2
The efficacy of treatment modalities hired for FFA treatment.
| | Treatment modality (number of administered patients) | Monotherapy | Combination therapy (with other treatment modalities) | | Improved | Stabilized | Worsened | Improved | Stabilized | Worsened |
| | ITAIs (n = 287) | 45 (16%) | 106 (37%) | 14 (5%) | 33 (11%) | 71 (25%) | 18 (6%) | | Oral corticosteroids (prednisone) (n = 6) | — | — | 1 (17%) | — | — | 5 (83%) | | 5-alpha-reductase inhibitors (finasteride/dutasteride) (n = 508) | 77 (15%) | 78 (15%) | 9 (2%) | 18 (4%) | 250 (49%) | 76 (15%) | | Oral isotretinoin/alitretinoin (n = 38) | 13 (34%) | — | 3 (8%) | 22 (58%) | — | — | | HCQ (n = 256) | 25 (10%) | 37 (15%) | 26 (10%) | 32 (12%) | 85 (33%) | 51 (20%) | | Topical minoxidil 5% (n = 101) | 7 (7%) | — | — | 13 (13%) | 72 (71%) | 9 (9%) | | Doxycycline (n = 20) | 2 (10%) | — | 2 (10%) | 7 (35%) | — | 9 (45%) | | Topical corticosteroids (n = 312) | 1 (0.3%) | — | — | 82 (26%) | 117 (37.5%) | 112 (35.2%) | | Topical tacrolimus/pimecrolimus (n = 140) | — | — | — | 84 (60%) | 52 (37%) | 4 (3%) | | Topical retinoids (n = 9) | — | — | — | 3 (33%) | 6 (67%) | — | | Oral minoxidil (n = 8) | 7 (87.5%) | — | — | 1 (12.5%) | — | — | | Methotrexate (n = 4) | — | 2 (50%) | 2 (50%) | — | — | — | | PRP (n = 8) | 1 (12.5%) | — | — | 7 (87.5%) | — | — | | Tildrakizumab (n = 1) | — | — | — | 1 (100%) | — | — | | Intramuscular steroids (n = 18) | — | — | — | 15 (83%) | — | 3 (17%) | | LED (n = 16) | 16 (100%) | — | — | — | — | — | | Nd:YAG nonablative laser (n = 5) | 5 (100%) | — | — | — | — | — | | Hair transplantation (n = 60) | 1 (2%) | — | 57 (95%) | 2 (3%) | — | — | | Topical bimatoprost ophthalmic solution 0.03% (n = 4) | 1 (25%) | — | — | 3 (75%) | — | — |
|
|
